Selection of lansoprazole from an FDA-approved drug library to inhibit the Alzheimer’s disease seed-...
Selection of lansoprazole from an FDA-approved drug library to inhibit the Alzheimer’s disease seed-dependent formation of tau aggregates
About this item
Full title
Author / Creator
Publisher
Switzerland: Frontiers Research Foundation
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: Frontiers Research Foundation
Subjects
More information
Scope and Contents
Contents
The efficacy of current treatments is still insufficient for Alzheimer’s disease (AD), the most common cause of Dementia. Out of the two pathological hallmarks of AD amyloid-β plaques and neurofibrillary tangles, comprising of tau protein, tau pathology strongly correlates with the symptoms of AD. Previously, screening for inhibitors of tau aggrega...
Alternative Titles
Full title
Selection of lansoprazole from an FDA-approved drug library to inhibit the Alzheimer’s disease seed-dependent formation of tau aggregates
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_160579159a284f1596db2265a64b6963
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_160579159a284f1596db2265a64b6963
Other Identifiers
ISSN
1663-4365
E-ISSN
1663-4365
DOI
10.3389/fnagi.2024.1368291
